Innoblative
Our core values are to drive innovation, improve patient experience, and impact economics.
Our core values are to drive innovation, improve patient experience, and impact economics.
Recently, Innoblative has attracted Seed Round investment from Pioneer Healthcare Partners on 01 October 2021. The company, founded in 2013 and headquartered in the United States, operates with the slogan "Our core values are to drive innovation, improve patient experience, and impact economics."
Innoblative is a private medical device company that focuses on addressing clinical unmet needs for patients with breast cancer and other soft tissue diseases. The company is dedicated to developing advanced energy-based surgical solutions to enhance the way surgeons coagulate and ablate soft tissue, ultimately striving to offer improved care for patients.
Notably, Innoblative has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its SIRA® RFA Electrosurgical Device. Although the SIRA® device is investigational for use in breast conserving surgery (BCS) and not available for sale in the United States, it is cleared for intraoperative coagulation and ablation of soft tissue. This significant achievement highlights the company's commitment to pioneering advancements in medical technology.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 |
|
01 Oct 2021 |
| Venture Round | Unknown | 1 | Alumni Ventures | 08 Feb 2018 |
| Grant | $680.66K | 1 |
|
22 Sep 2017 |
| Series A | $7.20M | 2 |
|
05 May 2017 |
| Grant | $225.00K | 1 |
|
24 Jun 2016 |
No recent news or press coverage available for Innoblative.
We care about your data, and we'd love to use cookies make your experience better.
